Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.50 |
| ▸ | EP300 | Q09472 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.46 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8360870 | 0.86 | NR1D1 (0.48) | ALDH1A1LMNAHSD17B10SMN1; SMN2NPSR1 | |
| SCHEMBL8360879 | 0.86 | JAK2 (0.51) | ALDH1A1LMNAPSEN1PSEN2APH1B | |
| SCHEMBL8363842 | 0.84 | CNR1 (0.54) | ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL8363942 | 0.82 | MMP1 (0.50) | ALDH1A1LMNAPSEN1PSEN2APH1B | |
| SCHEMBL8363934 | 0.81 | MMP1 (0.48) | ALDH1A1LMNAPSEN1PSEN2APH1B | |
| SCHEMBL2336091 | 0.81 | ALDH1A1 (0.66) | ALDH1A1LMNAHSD17B10SMN1; SMN2HIF1A | |
| SCHEMBL8360876 | 0.80 | KCNA5 (0.55) | ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL8360843 | 0.80 | CNR1 (0.49) | ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL8360883 | 0.79 | STS (0.44) | ALDH1A1HSD17B10SMN1; SMN2PSEN1PSEN2 | |
| SCHEMBL8363938 | 0.79 | CNR1 (0.46) | ALDH1A1LMNAHSD17B10SMN1; SMN2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270902-A1 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2012-10-25 | — | — | US | claimed |
| EP-1723102-A2 | N-SUBSTITUTED BENZENE SULFONAMIDES | Elan Pharmaceuticals, Inc. (US) | 2006-11-22 | — | — | EP | claimed |
| US-20050245573-A1 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. | 2005-11-03 | — | — | US | claimed |
| WO-2005090296-A2 | N-SUBSTITUTED BENZENE SULFONAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| US-20120270902-A1 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-8193389-B2 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| EP-2374792-A1 | N-substituted benzene sulfonamides | Elan Pharmaceuticals Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-2360142-A1 | N-substituted benzene sulfonamides | Elan Pharmaceuticals Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| EP-1723102-A2 | N-SUBSTITUTED BENZENE SULFONAMIDES | Elan Pharmaceuticals, Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20050245573-A1 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005090296-A2 | N-SUBSTITUTED BENZENE SULFONAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245573-A1 | N-substituted benzene sulfonamides | PSEN1, PSEN2, BCHE | ALDH1A1 665/4885LMNA 3051/4885HSD17B10 1761/4885 |
| US-20120270902-A1 | N-substituted benzene sulfonamides | PSEN1, PSEN2, BCHE | ALDH1A1 665/4885LMNA 3051/4885HSD17B10 1761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.